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Activation of the thiol protease calpain results in pro-
teolysis of focal adhesion-associated proteins and sever-
ing of cytoskeletal-integrin links. We employed a com-
monly used inhibitor of calpain, calpeptin, to examine a
role for this protease in the reorganization of the cy-
toskeleton under a variety of conditions. Calpeptin in-
duced stress fiber formation in both forskolin-treated
REF-52 fibroblasts and serum-starved Swiss 3T3 fibro-
blasts. Surprisingly, calpeptin was the only calpain in-
hibitor of several tested with the ability to induce these
effects, suggesting that calpeptin may act on targets
besides calpain. Here we show that calpeptin inhibits
tyrosine phosphatases, enhancing tyrosine phosphoryl-
ation particularly of paxillin. Calpeptin preferentially
inhibits membrane-associated phosphatase activity.
Consistent with this observation, in vitro phosphatase
assays using purified glutathione S-transferase fusion
proteins demonstrated a preference for the transmem-
brane protein-tyrosine phosphatase-a over the cytosolic
protein-tyrosine phosphatase-1B. Furthermore, unlike
wide spectrum inhibitors of tyrosine phosphatases such
as pervanadate, calpeptin appeared to inhibit a subset
of phosphatases. Calpeptin-induced assembly of stress
fibers was inhibited by botulinum toxin C3, indicating
that calpeptin is acting on a phosphatase upstream of
the small GTPase Rho, a protein that controls stress
fiber and focal adhesion assembly. Not only does this
work reveal that calpeptin is an inhibitor of protein-
tyrosine phosphatases, but it suggests that calpeptin
will be a valuable tool to identify the phosphatase activ-
ity upstream of Rho.
The small GTP-binding protein Rho belongs to the larger Ras
family of small GTPases and has been demonstrated to regu-
late cytoskeletal reorganization, stimulating the formation of
stress fibers and focal adhesions in cultured cells (1). Charac-
teristic of all Ras family members, Rho functions as a “molec-
ular switch” in the cell (2–4), cycling between inactive GDP-
bound and active GTP-bound states. The rate of activation and
inactivation of this GTPase is regulated by a number of pro-
teins, including guanine nucleotide exchange factors, GTPase-
activating proteins, and guanine nucleotide dissociation inhib-
itors (2). Although considerable insight has been gained into
the mechanisms regulating small GTPases such as Rho, many
components along the Rho signaling pathway remain to be
identified.
Protein tyrosine phosphorylation and/or dephosphorylation
events play a major role in the Rho-mediated regulation of
cytoskeletal reorganization. Evidence for this comes from the
use of inhibitors of protein-tyrosine kinases such as genistein
(5, 6), erbstatin (6), and tyrphostin 25 (7), which have been
demonstrated to inhibit the activation of Rho and prevent
cytoskeletal assembly. Consistent with this, studies using pro-
tein-tyrosine phosphatase (PTPase)1 inhibitors, such as per-
vanadate (6, 8, 9) and phenylarsine oxide (PAO) (10, 11), have
demonstrated induction of stress fibers in serum-starved cells.
Since these inhibitors block the enzymatic activity of a wide
range of kinases and phosphatases, it is unclear which en-
zyme(s) are responsible for Rho regulation in these instances.
In addition, studies artificially overexpressing soluble PTPases
(through microinjection or scrape loading) resulted in disas-
sembly of stress fibers and focal adhesions (12). Although there
is increasing evidence for PTPases as important players in the
regulation Rho and cytoskeletal reorganization (13–16), the
identity of the enzyme(s) lying upstream of Rho activation
remains elusive.
The second messenger cAMP also exerts dramatic effects on
cytoskeletal architecture. Elevation of cAMP in a variety of cell
types induces loss of actin stress fibers and focal adhesions,
rounding of cells, and in some cases detachment from the
underlying substratum (17–19). Increases in intracellular
cAMP also decrease the phosphorylation of multiple proteins,
including the tyrosine phosphorylation of focal adhesion pro-
teins paxillin (20) and pp125FAK (21) and the phosphorylation
of myosin light chain (22). Although the mechanism(s) eliciting
the effects of cAMP appear to be complex, recent studies (23–
27) point toward a role for this cyclic nucleotide in the down-
regulation of Rho. There may be multiple ways in which cAMP
can regulate cytoskeletal reorganization, and they may all par-
ticipate to some extent in the cytoskeletal disassembly associ-
ated with cAMP elevation.
One potential candidate that may play a role in the disas-
sembly of cytoskeletal structures is the ubiquitous thiol prote-
ase calpain. This enzyme localizes to focal adhesions (28, 29),
where it has been shown to participate in the limited proteol-
ysis of numerous structural and signaling proteins associated
with these adhesions (30–34). The proteolytic actions of calpain
have been postulated to destabilize focal adhesions and sever
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the linkage between the extracellular matrix and the contract-
ile cytoskeleton of the cell (35, 36). Consistent with this, several
recent reports have confirmed a role for calpain in the down-
regulation of cell processes such as spreading (37), migration
(36), and platelet-mediated clot retraction (35, 38). The possible
participation of calpain in events requiring remodeling of the
cytoskeleton prompted us to investigate the role of this prote-
ase in disassembly of the cytoskeleton. Surprisingly, we found
that treatment of cells with calpeptin, an inhibitor of calpain,
was sufficient to induce stress fiber formation, focal adhesions,
and cell contractility. This effect was specific for calpeptin and
could not be mimicked by other calpain inhibitors. Further-
more, calpeptin-induced formation of stress fibers and focal
adhesions was inhibited by botulinum toxin C3, suggesting
that the calpeptin target was upstream of Rho. We report
that calpeptin cross-reacts with another family of enzymes,
PTPases, which also possess a critical cysteine in their active
site. Using this knowledge, we provide evidence for the exist-
ence of a PTPase activity, associated with the membrane frac-
tion of cells, which acts upstream of Rho.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Calpeptin, PAO, calpain inhibitor 1 (CI-1),
recombinant calpastatin, and E64d were obtained from Calbiochem-
Novabiochem. Forskolin was purchased from Biomol Research Labora-
tories (Plymouth Meeting, PA). Dibutyryl cAMP and Protein A-Sepha-
rose were from Sigma. Glutathione-Sepharose 4B was obtained from
Amersham Pharmacia Biotech (Uppsala, Sweden). Transfer polyvinyli-
dene difluoride membranes were obtained from Millipore Corp. (Bed-
ford, MA). Radiochemicals were from NEN Life Science Products. A
cyclic AMP 3H assay system was purchased from Amersham Interna-
tional (Buckinghamshire, United Kingdom). Antiphosphotyrosine poly-
clonal, antiphosphotyrosine PY20, and anti-paxillin monoclonal anti-
bodies were purchased from Transduction Laboratories (Lexington,
KY). Anti-mouse peroxidase-conjugated IgG was from Jackson Labora-
tories (West Grove, PA). Fluorescein-conjugated rabbit IgG and rabbit
anti-mouse IgG were from Chemicon (Temecula, CA). Rhodamine-con-
jugated phalloidin was from Molecular Probes, Inc. (Eugene, OR).
Fluorescein-conjugated anti-human IgG for microinjection was from
ICN/Cappel (Aurora, OH). GST constructs for the recombinant PTPases
and botulinum toxin C3 were generous gifts from various research
laboratories. The catalytic domain of PTP-1B (PTP-37K-1B) (Dr. J.
Dixon, University of Michigan), cytoplasmic domain of PTPa (Dr. M.
Thomas, Washington University, St. Louis, MO), PTEN (Dr. N. Tonks,
Cold Spring Harbor, NY), and C3 exotransferase (Dr. L. Feig, Tufts
University, Boston, MA).
Cell Culture—Swiss 3T3 fibroblasts and REF-52 fibroblasts were
maintained in DMEM as described previously (6). Swiss 3T3 fibroblasts
were serum-starved by incubation in DMEM lacking serum for at least
24 h.
Drug Treatment—In some experiments, cells were preincubated with
vehicle alone (Me2SO) (0.1%, v/v) or one of the following compounds:
calpeptin (0.1–1.0 mg/ml), E-64d (100 mM), CI-1 (10 mM), pervanadate
(50 mM), EGTA/MgCl2 (1 and 2 mM, respectively), or PAO (1 mM). Cells
were incubated with these compounds for 30 min at 37 °C, unless
otherwise indicated.
Immunofluorescence Microscopy—Immunofluorescence microscopy
was performed as described previously (6).
Preparation of Whole Cell Lysates and Subcellular Fractions—Whole
cell lysates were prepared as described previously (6). For isolation of
cytosol and membrane fractions, adherent cells were scraped into re-
suspension buffer (5 mM Tris, pH 7.6, 0.25 M sucrose, 2 mM EDTA, 10
mg/ml leupeptin, 25 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluo-
ride), sonicated six times (8 s each), and then centrifuged at 1,000 3 g
to remove intact cells and nuclei. Cytosol and membrane fractions were
isolated by centrifugation at 100,000 3 g for 30 min. The membrane
pellet was resuspended in Triton X-100-containing buffer. Measure-
ment of protein concentration was determined using the Coomassie
Protein Assay Reagent, with bovine serum albumin as a standard,
following the manufacturer’s instructions (Pierce).
Immunoprecipitation and Immunoblotting—Immunoprecipitation of
paxillin or phosphotyrosine-containing proteins was performed as de-
scribed previously (6). Cell lysates or immunoprecipitated samples were
separated by 10% SDS-polyacrylamide gel electrophoresis (39) under
reducing conditions and then transferred to polyvinylidene difluoride
membranes. Western blots were performed as described by Towbin et
al. (40). Blots were developed using SuperSignal Substrate for Western
blotting (Pierce).
Preparation of Pervanadate—Vanadate stock solution was prepared
essentially as described (41). Pervanadate (50 mM) was prepared by
combining 100 ml of vanadate, 88 ml of Tris-buffered saline, and 12 ml of
30% hydrogen peroxide. The pervanadate solution was used within 5
min of preparation.
Measurement of Intracellular cAMP Levels—Intracellular cAMP lev-
els were measured as described by Yuan et al. (42), using a 3H-labeled
cyclic AMP assay system according to the manufacturer’s instructions
(Amersham Pharmacia Biotech).
Growth and Purification of GST Fusion Proteins—The recombinant
catalytic subunit of PTP-1B (PTP-37K-1B), the cytoplasmic tail of
PTPa, PTEN, and C3 exotransferase were expressed as GST fusion
proteins in Escherichia coli (BL21) as described previously (43).
Microinjection of C3 Exotransferase or Calpastatin—Cells were
grown on coverslips and injected with either 100 mg/ml C3 exotrans-
ferase or 2 mg/ml recombinant calpastatin (diluted in microinjection
buffer (5 mM Tris, pH 7.6, 150 mM NaCl, 5 mM MgCl2 and 0.1 mM
dithiothreitol)). Cells were coinjected with fluorescein-conjugated anti-
human IgG in order to detect injected cells. Cells were returned to the
tissue culture incubator to allow for recovery (30–60 min).
In Vitro PTPase Assays—Whole cell lysates or subcellular fractions
from forskolin-treated (10 mM, 30 min) REF-52 or serum-starved (24 h)
Swiss 3T3 fibroblasts were prepared as described previously (44).
[32P]poly(Glu:Tyr) substrate was prepared according to the method of
Burridge and Nelson (45). All assays were performed within the linear
range with respect to protein-tyrosine phosphatase activity. Samples
were diluted in phosphatase assay buffer (50 mM Tris, pH 7.0, 1 mg/ml
BSA, 0.3% b-mercaptoethanol, 50 mM EDTA) to a final volume of 100 ml.
Reactions were started by the addition of [32P]poly(Glu:Tyr) (approxi-
mately 40,000 cpm) and incubated at 30 °C for 5–20 min. Reactions
were terminated by the addition of an equal volume of 20% trichloro-
acetic acid. Tubes were incubated on ice for 10 min and vortexed, and
the precipitated protein was pelleted by centrifugation in a microcen-
trifuge at 12,000 rpm for 2 min. The supernatant was removed and
added to 2 ml of scintillation fluid. Phosphatase activity was deter-
mined by the amount of free label released into the supernatant meas-
ured by scintillation counting, minus the amount of label released in the
absence of lysate. Results are expressed as the mean of several inde-
pendent experiments.
RESULTS
Activation of the thiol protease calpain has been demon-
strated to result in the down-regulation of a number of cellular
processes including cell spreading, migration, and contraction
(35–38). These processes are all dependent on reorganization of
the cytoskeleton. In addition, calpain is localized to focal adhe-
sions, where its activation has been shown to correlate with the
proteolysis and loss of various structural and signaling pro-
teins (30–34) from these sites and the disruption of integrin-
cytoskeletal linkages (35, 36). These studies imply a potentially
important role for calpain in the disassembly of cytoskeletal
architecture. To investigate this possibility, we searched for
cell models that could easily be manipulated to induce cytoskel-
etal disassembly. We chose a rat fibroblast cell line (REF-52) as
one of our cell models, since these cells have been demonstrated
to rapidly and reversibly lose stress fibers and focal adhesions
in response to agents that elevate intracellular levels of cAMP
(e.g. forskolin, dibutyryl cAMP) (17, 46). With this cell model,
we set out to determine whether calpain was involved in the
disassembly of stress fibers and focal adhesions induced by
elevated cAMP levels.
Calpeptin Blocks the Disassembly of Stress Fibers—In order
to study the role of calpain inside the cell, it was necessary to
perturb the function of this protease. Several synthetic inhib-
itors have been produced that block calpain activity (47, 48).
One such inhibitor is calpeptin (49), a dipeptide aldehyde that
was designed to bind specifically to the critical cysteine residue
in the active site of calpain, preventing the binding and subse-
quent proteolysis of calpain substrates (48). Therefore, we be-
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gan our examination of the role of calpain in regulating the
disassembly of stress fibers in our chosen cell model, using
calpeptin. Under normal culture conditions, REF-52 fibroblasts
displayed a striking array of thick actin stress fibers (Fig. 1a,
A). This organization was dramatically lost in response to
treatment with 10 mM forskolin (elevation of cAMP) (Fig. 1a, B).
However, when these cells were treated with the calpain inhib-
itor calpeptin (100 mg/ml), prior to forskolin treatment, the cells
retained their normal actin organization and did not lose their
stress fibers (Fig. 1a, C). We found this effect to be dose-de-
pendent, with noticeable effects at concentrations of calpeptin
as low as 20 mg/ml (data not shown). To ensure that the effects
of calpeptin were not unique to forskolin, we also performed
similar studies using the cAMP derivative, dibutyryl cAMP.
Consistent with forskolin treatment, we found that calpeptin
could prevent the dibutyryl cAMP-induced loss of stress fibers
in REF-52 fibroblasts (data not shown). As a further control, we
measured intracellular cAMP levels using a 3H-labeled cAMP
assay system and confirmed that calpeptin was not merely
acting by lowering cAMP levels inside the cell (data not shown).
These results suggest that calpeptin was able to block the
disassembly of the cytoskeleton induced by intracellular cAMP
elevation.
The calpeptin-mediated effects on cAMP-induced disassem-
bly could be due to blocking disassembly or alternatively pro-
moting assembly of stress fibers. To explore the possibility that
calpeptin might promote stress fiber assembly, we examined
the effect of calpeptin on serum-deprived Swiss 3T3 cells. When
Swiss cells are starved of serum for up to 24 h, their actin stress
fibers will disassemble (Fig. 1b, A). Previous studies have dem-
onstrated that the addition of serum or serum components such
as lysophosphatidic acid will rapidly induce the formation of
stress fibers in starved cells via the activation of Rho (1).
Strikingly, when calpeptin was added to the serum-free culture
medium, Swiss 3T3 cells rapidly (within 30 min) reformed their
stress fibers (Fig. 1b, B), a response reminiscent of serum or
lysophosphatidic acid addition. These results are consistent
with those obtained using REF-52 fibroblasts and suggest that
calpeptin can promote the formation of stress fibers.
Calpain Is Not the Target for Calpeptin-mediated Inhibition
of Stress Fiber Disassembly—Although calpeptin has proven to
be an effective inhibitor of the calpain-mediated proteolysis of
several calpain substrates (30–34), like many other inhibitors
its specificity at higher concentrations is questionable. To con-
firm that calpain was the protein targeted for inhibition by
calpeptin, we tested a number of other calpain inhibitors
widely used in the literature. These inhibitors were used at
concentrations previously demonstrated to block calpain activ-
ity (35, 38). Surprisingly, preincubation of REF-52 fibroblasts
(Fig. 2) or Swiss 3T3 fibroblasts (data not shown) with E64d
(100 mM) (Fig. 2a, D) or CI-1 (10 mM) (Fig. 2a, E) did not prevent
the forskolin-induced disassembly of stress fibers. Since cal-
pain is a calcium-dependent protease, we tried chelation of
calcium, which is an effective method of inhibiting calpain
activation. However, consistent with CI-1 and E64d, incubation
of REF-52 fibroblasts with a combination of EGTA (1 mM) and
Mg21 (2 mM) (Fig. 2a, F) had no effect on the forskolin-induced
disassembly of stress fibers. Finally and most convincingly, the
introduction of recombinant calpastatin (the endogenous and
highly specific inhibitor of calpain) into these cells did not block
forskolin-induced events (Fig. 2b). These results suggested that
calpain was not the target of calpeptin in these studies and
thus not responsible for the disassembly of stress fibers under
conditions of elevated intracellular cAMP or deprivation of
serum.
Further evidence ruling out calpain as the target of calpeptin
in these experiments came from studies in which we demon-
strated that calpeptin could reverse stress fiber disassembly,
even after forskolin treatment had been administered. REF-52
fibroblasts were incubated for 30 min with forskolin, conditions
that would allow for the complete disruption of stress fibers
(Fig. 2c, A). Calpeptin was then added to the culture medium,
in the continued presence of forskolin, and the cells incubated
for various time periods (Fig. 2c, B–D). Reappearance of stress
fibers was evident as early as 10 min after calpeptin addition,
and full recovery of stress fibers was achieved within 30 min.
This result is inconsistent with the notion that calpeptin is
inhibiting the activation of calpain, since proteolytic cleavage of
calpain substrates cannot be “reversed.” Furthermore, new
protein synthesis could not be responsible for the restoration of
stress fibers by calpeptin, since this process would not be sig-
nificant in the time scale of this experiment. Taken together,
these observations indicate that calpain is not the responsible
protease regulating stress fiber disassembly and suggest that
calpeptin is inhibiting some other protein(s) responsible for
cytoskeletal remodeling.
Calpeptin Mediates Its Effects via the Inhibition of PT-
Pases—Calpeptin is a dipeptide aldehyde whose mode of inhi-
FIG. 1. Calpeptin induces the for-
mation of stress fibers. REF-52 and
Swiss 3T3 fibroblasts were cultured in
complete DMEM and plated onto cover-
slips. a, REF-52 fibroblasts were preincu-
bated with vehicle (Me2SO) alone (A and
B) or 100 mg/ml calpeptin (C) for 30 min.
Cells were then treated with vehicle
(Me2SO) alone (A) or 10 mM forskolin (B
and C) for 30 min. b, Swiss 3T3 fibroblasts
were placed in serum-free medium and
starved for 24 h. Cells were then treated
with vehicle (Me2SO) alone (A) or 100
mg/ml calpeptin for 30 min (B). Both
REF-52 and Swiss 3T3 cells were fixed
and processed for fluorescence microscopy
as described under “Experimental Proce-
dures.” Cells were visualized by staining
with rhodamine-conjugated phalloidin.
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bition is via binding the active site cysteine of calpain (48, 49).
Since our results suggested that calpeptin was not promoting
stress fiber formation through inhibition of calpain, it was
necessary to determine other potential targets for the inhibitor.
One other group of enzymes with a critical cysteine residue in
their active site is the PTPases (50). To investigate the possi-
bility that calpeptin may inhibit PTPases, we initially exam-
ined the tyrosine phosphorylation pattern in both REF-52 and
Swiss 3T3 fibroblasts, under conditions where calpeptin had
previously been demonstrated to induce stress fiber formation
(see Fig. 1, a and b). We found that the tyrosine phosphoryla-
tion of several proteins was enhanced by calpeptin treatment
(Fig. 3a). In particular, we noted a dramatic increase in tyro-
sine phosphorylation of a protein migrating as a broad band
above the 64-kDa molecular mass marker. By performing im-
munoprecipitations of REF-52 cell lysates, we were able to
identify this protein as paxillin (Fig. 3b), a 68-kDa adapter
protein localized to focal adhesions. Paxillin has previously
been demonstrated to undergo rapid dephosphorylation in re-
sponse to intracellular cAMP elevation (20). Consistent with
this, we also found that paxillin was rapidly dephosphorylated
upon treatment with forskolin in REF-52 fibroblasts (Fig. 3c).
Furthermore, in correlation with immunofluorescence studies
demonstrating a calpeptin-mediated reversal of stress fiber
disassembly in forskolin-treated cells (Fig. 2c), the dephospho-
rylation of paxillin was completely reversed upon the addition
of calpeptin (Fig. 3c). These results are consistent with inhibi-
tion of a tyrosine phosphatase. Our attempts to determine the
identity of other proteins migrating around 36–40 and 110–
130 kDa that displayed changes in tyrosine phosphorylation
(albeit minor) were not successful. We examined the tyrosine
phosphorylation status of pp125FAK and p130cas, which have
previously been demonstrated to change in correlation with the
regulation of stress fibers and focal adhesions (8, 51–57). We
could not detect any significant changes in the tyrosine phos-
phorylation of either of these proteins in response to calpeptin.
Therefore, it appears at least in this system that paxillin, but
not p130cas or pp125FAK, displays changes in tyrosine phospho-
rylation during the calpeptin-mediated induction of stress
fibers.
FIG. 2. Calpeptin-mediated induction of stress fibers is not mediated through inhibition of calpain. REF-52 fibroblasts cultured in
complete DMEM were plated onto coverslips. a, cells were preincubated with vehicle (Me2SO) alone (A and B), 100 mg/ml calpeptin (C), 100 mM
E64d (D), 20 mM CI-1 (E), or 1 mM EGTA and 2 mM MgCl2 (F) for 30 min. Cells were then treated with vehicle (Me2SO) alone (A) or 10 mM forskolin
(B–F) for 30 min. b, cells were injected with recombinant calpastatin (2.0 mg/ml) along with fluorescein-conjugated anti-human IgG to identify
injected cells. Cells were then treated with vehicle (Me2SO) (A and B) or forskolin (10 mM) for 30 min (C and D). c, all cells were treated with 10
mM forskolin for 30 min (A–D). Following this, 100 mg/ml calpeptin was added, and cells were incubated for 0 (A), 10 (B), 20 (C), or 30 (D) min. Cells
were visualized by staining with rhodamine-conjugated phalloidin, as described under “Experimental Procedures.”
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To confirm the ability of calpeptin to act as a PTPase inhib-
itor, we next examined its ability to inhibit PTPase activity in
in vitro assays using an exogenous substrate. Whole cell lysates
from Swiss 3T3 and REF-52 fibroblasts were prepared as de-
scribed under “Experimental Procedures” and assayed for their
ability to remove the radiolabeled phosphate from [32P]poly-
(Glu:Tyr). The addition of cell lysates to the assay resulted in
the release of radiolabel from the substrate (Fig. 4, a and b,
DMSO). However, when calpeptin was included in these as-
says, PTPase activity in both Swiss 3T3 and REF-52 fibroblast
cell lysates was reduced by a small yet significant level (10–
20%) (Fig. 4, a and b, 100 mg/ml). It is important to note that
calpeptin was unable to fully inhibit the phosphatase activity
in these cell lysates, even at higher concentrations (Fig. 4, a
and b, 1.0 mg/ml). This suggests that calpeptin may not be a
very efficient inhibitor of PTPases or, alternatively, that it may
only target a subset of phosphatases in the whole cell lysate.
Calpeptin Preferentially Targets Membrane-associated PT-
Pases—PTPases can be divided into two broad categories, the
cytosolic enzymes and the transmembrane receptor type PT-
Pases (58, 59). We examined the possibility that calpeptin may
preferentially inhibit the activity of one of these categories by
performing in vitro PTPase assays on cytosolic and membrane
fractions prepared from REF-52 fibroblasts. Interestingly, cal-
peptin appeared to exert a greater inhibitory effect on the
phosphatase activity present in the membrane fraction of
REF-52 fibroblasts (79% inhibition) when compared with the
cytosolic fraction (35% inhibition) (Fig. 5a). This suggests that
calpeptin preferentially inhibits either transmembrane PT-
Pases or, alternatively, PTPases that are localized to the mem-
brane through their association with membrane proteins. Con-
sistent with an action on transmembrane PTPases, we found
that the effect of calpeptin on the phosphatase activity of GST-
PTPa (Fig. 5b, II), a transmembrane PTPase, was greater than
its effect on the cytosolic PTPase GST-PTP-1B (Fig. 5b, I). We
also tested the ability of this inhibitor to block the activity of a
phosphatase with dual specificity, PTEN, and found that cal-
peptin exerted a moderate inhibitory effect on PTEN (Fig. 5b,
III). In addition, preliminary kinetic studies performed on the
FIG. 3. Calpeptin enhances tyrosine phosphorylation of cellu-
lar proteins, including paxillin. REF-52 and Swiss 3T3 cells were
cultured in complete DMEM. REF-52 cells were pretreated with vehicle
(Me2SO) alone (A) or 100 mg/ml calpeptin (B) for 30 min, followed by
incubation with 10 mM forskolin for 30 min. Swiss cells were serum-
starved for 24 h and then incubated with vehicle (Me2SO) alone (C) or
100 mg/ml calpeptin (D) for 30 min. Whole cell lysates were prepared as
described under “Experimental Procedures.” a, equal amounts of pro-
tein were analyzed by 10% SDS-polyacrylamide gel electrophoresis,
followed by immunoblotting with an antiphosphotyrosine antibody
(PY20). b, equal amounts of proteins from REF-52 cell lysates were used
to immunoprecipitate paxillin, as described under “Experimental Pro-
cedures.” Immunoblot analysis of immunoprecipitates was performed
using an anti-phosphotyrosine antibody (PY20). A lower band of ap-
proximately 55 kDa present in both lanes represents the mouse IgG
heavy chain. c, REF-52 fibroblasts were incubated with 10 mM forskolin
for the indicated times. Following 20 min of forskolin incubation, 100
mg/ml calpeptin was included in the cell medium. After the completion
of the time course, whole cell lysates were prepared as described pre-
viously, and equal amounts of lysate were analyzed by immunoblotting
using an anti-phosphotyrosine monoclonal antibody, PY20.
FIG. 4. Calpeptin directly inhibits whole cell lysate PTPase
activity in vitro. Swiss 3T3 and REF-52 fibroblasts were cultured in
complete DMEM. Whole cell lysates were prepared from forskolin-
treated REF-52 fibroblasts (a) or serum-starved Swiss 3T3 cells (b) as
described under “Experimental Procedures.” In vitro PTPase assays
were performed on equal amounts of protein from cell lysates as de-
scribed, in the presence of vehicle (Me2SO (DMSO)) alone or 100 mg/ml
or 1.0 mg/ml calpeptin. All assays were performed within the linear
range with respect to PTPase activity. Phosphatase activity is ex-
pressed as the amount of 32P label released from [32P]poly(Glu:Tyr) and
reflects the mean 6 S.D. from several independent experiments.
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mode of calpeptin-mediated inhibition of PTPa suggested that
inhibition is most likely competitive in nature (data not
shown). This is similar to the mechanism of its inhibition of
calpain and consistent with an active site-directed inhibitor.
Comparisons made between the calpeptin-mediated inhibi-
tion of PTPases and that of two widely used PTPase inhibitors
(pervanadate and PAO) provided further evidence that calpep-
tin was selectively inhibiting a subset of PTPases. Both per-
vanadate (8, 9) and PAO (10, 11) have previously been demon-
strated to induce stress fiber formation. In our cell system,
pervanadate and PAO both prevented the forskolin-mediated
disassembly of stress fibers in REF-52 fibroblasts (Fig. 6a, PV
and PAO) and increased tyrosine phosphorylation of cellular
proteins, including paxillin (Fig. 6b, PV and PAO). Pervana-
date is an irreversible and universal inhibitor of PTPases (58),
as demonstrated by its ability to induce an extremely high level
of tyrosine phosphorylation (Fig. 6, a and b, PV). In contrast,
PAO, which has been suggested to selectively inhibit mem-
brane PTPases (61), targets only those PTPases containing
vicinal thiol groups, and induces only a modest increase in
tyrosine phosphorylation (Fig. 6, a and b, PAO). Calpeptin
appeared to mimic the response displayed by PAO (Fig. 6, a and
b, CP) and induced only a small increase in the tyrosine phos-
phorylation in REF-52 fibroblasts.
We have used a number of experimental strategies in an
attempt to identify the calpeptin-sensitive membrane-associ-
FIG. 5. Calpeptin exerts greater inhibitory effects on mem-
brane-associated PTPases in vitro. Cytosolic (Cyt) and membrane
(PM) fractions from forskolin-treated REF-52 fibroblasts (a) and GST-
PTP-1B (I), GST-PTPa (II), and GST-PTEN (III) (b) were prepared as
described under “Experimental Procedures.” In vitro PTPase assays
were performed in the absence or presence of calpeptin (100 mg/ml (a) or
1.0 mg/ml (b)) as described for Fig. 4.
FIG. 6. The effect of various PTPase inhibitors on forskolin-
induced disassembly of stress fibers and protein-tyrosine phos-
phorylation. REF-52 fibroblasts were cultured in complete DMEM on
coverslips or 100-mm tissue culture dishes. Cells were pretreated with
vehicle (Me2SO) alone (control), 100 mg/ml calpeptin (CP), 10 mM CI-1,
50 mM pervanadate (PV), or 1 mM PAO for 30 min. Cells were then
treated with 10 mM forskolin for 30 min. a, cells were visualized by
double staining for actin and phosphotyrosine using rhodamine-conju-
gated phalloidin and a polyclonal antiphosphotyrosine antibody fol-
lowed by a fluorescein-conjugated anti-rabbit secondary antibody. b,
whole cell lysates were prepared as described under “Experimental
Procedures,” and equal amounts of proteins were analyzed by immuno-
blot analysis using an anti-phosphotyrosine antibody, PY20.
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ated PTPase. One of these was the PTPase in-gel assay (45),
which provides a method of detecting phosphatase activity
while identifying the molecular weight of the enzyme. We have
tried to modify this assay to identify the calpeptin-sensitive
PTPase by including calpeptin in the renaturation procedure.
This technique relies on effective renaturation of the enzyme(s)
following SDS-polyacrylamide gel electrophoresis, and al-
though it works well for cytoplasmic PTPases, it is unfortu-
nately ineffective for studying membrane PTPases, since they
do not renature sufficiently to detect any significant activity.
Therefore, if calpeptin is primarily inhibiting membrane
PTPases, it is not surprising that we did not detect changes in
any of the bands appearing in this assay.
Calpeptin Induces Cell Contractility—The formation of actin-
rich stress fibers and the clustering of integrins and signaling
proteins to focal complexes are hallmark responses of activa-
tion of the small GTPase Rho. Rho activation has also been
shown to stimulate cell contractility (62, 63). Since calpeptin
was able to induce the formation of stress fibers and focal
adhesions, we were interested in determining whether calpep-
tin could also induce cell contractility. REF-52 fibroblasts were
incubated with calpeptin for a time period of 30 min, and cells
were monitored in real time using video microscopy (Fig. 7a).
Alternatively, cells were fixed and stained at certain points
throughout the same time course to examine their actin stress
fibers (Fig. 7b). Fig. 7 depicts sequential frames, each 15 min
apart and covering a length of 30 min. As demonstrated in the
control, where the vehicle alone (Me2SO (DMSO)) (Fig. 7a,
A–C) was added to the medium, the morphology of the cells did
not change dramatically over the 30-min time period. However,
when calpeptin was added to the medium, a significant con-
traction of the cells occurred (Fig. 7a, D–F), which was evident
even as early as 15 min. This contractile morphology is strik-
ingly similar to that observed in Swiss 3T3 fibroblasts micro-
injected with constitutively activated recombinant Rho (64).
Contractility of fibroblasts was also observed by Rhodamine-
phalloidin staining of cells incubated with calpeptin at similar
time points (Fig. 7b). These results suggest that calpeptin not
only induces the formation of stress fibers but also regulates
the contractile behavior of cells, both of which are associated
with activation of Rho.
Calpeptin Inhibits a PTPase Upstream of Rho—Since the
effect of calpeptin on cells appeared to mimic Rho activation,
we next examined if the effects of calpeptin were being exerted
upstream or downstream of Rho. The Rho inhibitor, C3 exo-
transferase, was microinjected into REF-52 fibroblasts, and
cells were allowed to recover for 60 min. Within this time, cells
injected with C3 lost their stress fibers as a consequence of Rho
inactivation. Cells were then treated with calpeptin. If acting
at a site upstream of Rho, we would expect that calpeptin
FIG. 7. Calpeptin induces cell con-
tractility. REF-52 fibroblasts were cul-
tured in complete DMEM on 60-mm tis-
sue culture dishes or coverslips. Cells
were treated with vehicle (Me2SO
(DMSO)) alone or 100 mg/ml calpeptin for
30 min. a, the morphology of live cells was
monitored in the presence of 25 mM
Hepes, pH 7.3, and recorded using video
microscopy. b, cells cultured on coverslips
were fixed and processed for fluorescence
microscopy. Cells were visualized by
staining for actin using rhodamine-conju-
gated phalloidin. Panels depict cells after
0, 15, and 30 min of incubation with
Me2SO (A–C) or calpeptin (D–F). Note the
smaller “contracted phenotype” of the
cells at 15 and 30 min.
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would not be able to bypass C3-inactivated Rho and induce
stress fiber formation in injected cells. However, if calpeptin
was acting downstream of Rho activation, stress fiber forma-
tion should be induced upon calpeptin treatment. As demon-
strated in Fig. 8 (C–F), calpeptin was not able to reverse the
disassembly of stress fibers induced by C3. This suggests that
calpeptin is acting on a PTPase upstream of Rho. Studies are
under way to identify the PTPase targeted by calpeptin.
DISCUSSION
The Rho family of small GTPases play an essential role in
actin reorganization (3, 4). Therefore, their regulation has im-
portant implications for processes such as embryonic develop-
ment, cell migration, and wound healing. The elucidation of
signaling components regulating Rho and its family members
is consequently integral to a better understanding of these
basic cellular events. The studies presented here define a novel
role for calpeptin, a widely used inhibitor of calpain, as an
inhibitor of PTPases. In doing so, we have identified a calpep-
tin-sensitive PTPase activity that acts as a regulator of Rho
and cytoskeletal reorganization. The calpeptin-sensitive
PTPase described in this report induces a number of the char-
acteristic responses associated with Rho activation, such as
formation of stress fibers and focal adhesions, as well as the
induction of cell contractility. Furthermore, its actions are
blocked by the Rho inhibitor C3 exotransferase, suggesting
that it is acting upstream of Rho. Although numerous guanine
nucleotide exchange factors have been identified that act up-
stream of Rho to regulate its activation state, signaling events
linking cell receptor stimulation and guanine nucleotide ex-
change factor activity are relatively unexplored.
Involvement of PTPases is not a new concept in the area of
Rho regulation. Studies using various inhibitors of tyrosine
kinases (genistein, erbstatin, tyrphostin 25) (5–7) or phos-
phatases (pervanadate, PAO) (8–11) have implicated tyrosine
phosphorylation events both upstream and downstream of Rho
activation. But information regarding the responsible enzymes
mediating this regulation remains to be identified. Recent re-
ports have provided some insight into the potential identity of
some PTPases with the ability to regulate cell migration and
stress fiber and focal adhesion formation. The tumor suppres-
sor PTEN, a phosphatase with dual specificity, was identified
as a regulator of cell migration and spreading (15). 2-Fold
overexpression of PTEN down-regulated focal adhesions and
stress fibers. However, whereas we did not detect any signifi-
cant changes in pp125FAK tyrosine phosphorylation, a 60%
decrease in the tyrosine phosphorylation of this protein was
observed in response to PTEN expression, with no detectable
changes in the tyrosine phosphorylation of paxillin. In addition,
more recent studies suggest that the cellular effects of PTEN
may not be the result of modulating the enzyme’s tyrosine
phosphatase activity but may be attributed to the phosphati-
dylinositol lipid phosphatase activity of PTEN (65–68). Yu et
al. (13) have reported that cells deficient in functional SHP-2,
a ubiquitous cytosolic PTPase, exhibit delayed spreading, re-
duced cell migration, an increased number of focal adhesions,
and reduced pp125FAK dephosphorylation. However, deletion of
SHP-2 from cells appears to have no dramatic effects on the
tyrosine phosphorylation of paxillin, in contrast with the cal-
peptin-sensitive PTPase described in this report. Finally, re-
cent studies have demonstrated that overexpression of PTP-1B,
also a cytosolic PTPase, in 3Y1 rat fibroblasts not only resulted
in impaired cell adhesion but also interfered with cell spread-
ing, migration, cytoskeletal architecture, and focal adhesion
formation (14). However, a separate study using different cell
lines showed no effect on cell morphology when overexpressing
PTP-1B (69). Instead, this latter study showed decreased fo-
cal adhesions when an inactive form of the PTPase was
overexpressed.
A role for calpain in the regulation of PTPase activity has
been reported. Calpain has been shown to proteolyze the cyto-
solic PTPases PTP-1B (32) and PTP-MEG (44), increasing their
enzymatic activity. Although we demonstrate reduced PTPase
activity with the addition of the calpain inhibitor calpeptin,
several lines of evidence rule out calpain activation as respon-
sible for changes in phosphatase activity in this report. First,
we could not demonstrate a role for calpain in forskolin-induced
or serum deprivation-induced disassembly of stress fibers, us-
ing any other calpain inhibitor available, including the highly
specific calpastatin. Second, chelation of calcium, which inhib-
its calcium-dependent calpain activation, does not mimic cal-
peptin-induced cellular effects. Third, forskolin treatment or
serum starvation of cells does not appear to induce the
characteristic cleavage of PTP-1B (32, 38) associated with cal-
pain activation.2 Therefore, we can conclude that changes in
PTPase activity seen in our studies are not the consequence of
calpain activation.
The second important issue brought to light in this report
concerns the specificity of calpeptin. The original design of
calpeptin as a calpain inhibitor focused on manipulating the
interaction formed between the active site of the protease and
its substrates (48, 49). As is the case with other cysteine pro-
teases, the protease domain of calpain contains a cysteine
residue (Cys108) that is essential for its proteolytic activity.
This cysteine residue participates in the formation of a thio-
ester intermediate between the protease and its substrate.
2 S. M. Schoenwaelder and K. Burridge, unpublished observations.
FIG. 8. Calpeptin exerts its actions upstream of Rho. REF-52
fibroblasts cultured in complete DMEM on coverslips were microin-
jected with fluorescein-conjugated anti-human IgG (A and B) or co-
injected with fluorescein-conjugated anti-human IgG and 100 mg/ml C3
exotransferase (C–F), as described under “Experimental Procedures.”
Cells were allowed to recover for 60 min and then treated with 100
mg/ml calpeptin for 30 min. Cells were visualized by staining for actin
using rhodamine-conjugated phalloidin. Injected cells were identified
by positive fluorescein staining. Note that cells injected with C3 lack
stress fibers even in the presence of calpeptin.
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Other residues surrounding the active site cysteine may also
play some role in this process. This information was used to
design an inhibitor that would (in theory) recognize calpain but
not other cysteine proteases. Unfortunately, although calpep-
tin does exhibit higher specificity toward calpain than other
calpain inhibitors that were produced in the past, when used at
higher concentrations it has also been demonstrated to inhibit
other cysteine proteases such as papain (48). We now report
that calpeptin inhibits another species of enzyme containing an
active site cysteine, the PTPases. We find that concentrations
of calpeptin thought previously to be specific for calpain (20–
100 mg/ml) also appear to inhibit a subset of PTPases both in
vitro and in vivo. Preliminary kinetic analyses suggest that
calpeptin’s mode of PTPase inhibition is most likely competi-
tive, similar to that of its inhibition of calpain. This new infor-
mation highlights the dangers of relying solely on the results
provided by a single pharmacological inhibitor.
In conclusion, we have identified a PTPase activity, associ-
ated with the membrane fraction of cells, which appears to play
an important role upstream in the regulation of the small
GTPase Rho. From our preliminary characterizations of this
enzyme activity, it appears to effectively induce the formation
of stress fibers, focal adhesions, and cell contractility, similar to
the actions of Rho activators such as serum or lysophosphatidic
acid. Although little is known about the identity of this mem-
brane-associated phosphatase, we hope to utilize the novel
application of calpeptin as a PTPase inhibitor to establish its
identity and define some of the signaling components that
lie upstream of Rho in the regulation of cytoskeletal
reorganization.
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